|
業務類別
|
Biotechnology |
|
業務概覽
|
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension. |
| 公司地址
| 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517 |
| 電話號碼
| +1 919 855-2100 |
| 傳真號碼
| +1 919 855-2133 |
| 公司網頁
| https://www.tenaxthera.com |
| 員工數量
| 16 |
| Mr. Christopher T. Giordano |
Director, President and Chief Executive Officer |
美元 563.73K |
22/04/2026 |
| Dr. Stuart Rich, M.D. |
Director and Chief Medical Officer |
美元 322.72K |
22/04/2026 |
| Mr. Thomas A. McGauley, C.P.A. |
Interim Chief Financial Officer and Principal Accounting Officer |
-- |
22/04/2026 |
|
|
| Mr. Christopher T. Giordano |
Director, President and Chief Executive Officer |
22/04/2026 |
| Dr. Stuart Rich, M.D. |
Director and Chief Medical Officer |
22/04/2026 |
| Ms. Robyn M Hunter |
Independent Director |
22/04/2026 |
| Dr. Michael Harvey Davidson, M.D. |
Independent Director |
22/04/2026 |
| Dr. June S. Almenoff, F.A.C.P.,M.D.,PhD |
Independent Director |
22/04/2026 |
| Dr. Declan Doogan, M.D. |
Independent Director |
22/04/2026 |
| Mr. Gerald T. Proehl |
Chairman of the Board |
22/04/2026 |
|
|
|
|
